{"id":"NCT03987620","sponsor":"Scynexis, Inc.","briefTitle":"Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis","officialTitle":"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis (AVVC).","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-06-07","primaryCompletion":"2020-03-29","completion":"2020-04-29","firstPosted":"2019-06-17","resultsPosted":"2021-09-08","lastUpdate":"2021-09-08"},"enrollment":455,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Candida Vulvovaginitis"],"interventions":[{"type":"DRUG","name":"Ibrexafungerp","otherNames":["SCY-078"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Ibrexafungerp (SCY-078)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase 3, randomized, multicenter, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral Ibrexafungerp (SCY-078) compared to placebo in female subjects 12 years and older with AVVC.","primaryOutcome":{"measure":"Clinical Cure (Complete Resolution of Signs and Symptoms)","timeFrame":"Day 8-14","effectByArm":[{"arm":"Ibrexafungerp (SCY-078)","deltaMin":119,"sd":null},{"arm":"Placebo","deltaMin":37,"sd":null}],"pValues":[]},"eligibility":{"minAge":"12 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":41,"countries":["United States","Bulgaria"]},"refs":{"pmids":["36255448"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":298},"commonTop":["Headache","Diarrhoea","Nausea"]}}